Coherent Launches OPSL at 552 nm for Life Sciences
Sapphire lasers are based on Coherent's unique optically pumped semiconductor laser (OPSL) technology. This is a well-proven technology with over 25,000 units currently in the field. One of the main benefits of OPSLs is wavelength scaling: the possibility to build OPSLs at nearly any visible wavelength. This has created a paradigm shift in visible laser applications where laser output is matched to key applications instead of vice versa. And, unlike most other solid-state lasers, OPSLs do not suffer from thermal lensing, so the output power of any Sapphire LP can be smoothly adjusted from 10% to 110% of nominal power with no effect on beam quality.
Sapphire 552 LP lasers are intended for life sciences applications including flow cytometry, confocal microscopy, and drug discovery. Because this wavelength is well-separated from established, popular laser wavelengths (e.g. 532 nm and 568 nm), it is ideal for instrument builders and end users looking to increase the number of fluorophores they can simultaneously detect without crosstalk.
Coherent Shared Services B.V.
Founded in 1966, Coherent, Inc. is a Russell 2000 Index company and a world leader in providing laser-based solutions to the commercial and scientific research markets. Please direct any questions to Andreas Zuck, Product Line Manager, at +49 (451) 3000-368, or 1 (800) 527-3786. For more information about Coherent, including product and financial updates, visit our website at http://www.Coherent.com.